IntroductionThis study aimed to analyze the midterm outcomes of LUMiC® endoprosthetic reconstruction following periacetabular resection of primary bone sarcomas and carcinoma metastases.Patients and MethodsWe retrospectively reviewed the charts of 21 patients (11 male [52.3%], 10 female [47.6%]; mean age 47 ± 16 years) for whom a LUMiC® endoprosthesis (Implantcast) was used to reconstruct a periacetabular defect after internal hemipelvectomy. The tumor was pathologically diagnosed as Ewing's sarcoma in six (28.5%), chondrosarcoma in 10 (47.6%), and bone metastasis from carcinoma in five (23.8%) patients.ResultsThe median follow‐up of patients was 57.8 months (95% confidence interval: 51.9–63.7). The implant survival rate at 1, 2, and 5 years were 95.2%, 85.7%, and 80.9%, respectively. The overall complication rate was 33.3% (n = 7). Four (19%) complications resulted in reconstruction failure. Total reoperation rate was 28.5% (n = 6). The complications were soft tissue failure/dislocation in two patients, aseptic loosening in one, infection in two, and local recurrence in two. At the time of study, seven patients were alive with no evidence of disease, seven were alive with disease, and seven died of disease. The 5‐year overall survival rate and local recurrence‐free survival rates were 67% and 76%, respectively. The median Musculoskeletal Tumor Society score at final follow‐up was 70% (range: 50%–86.6%).ConclusionWe conclude that LUMiC® endoprosthesis provides good functional outcomes and a durable reconstruct. Even though this reconstruction method presents some complications, it provides a stable pelvis in the management of periacetabular malignant tumors.
The new measures implemented in hospitals also altered the operation of orthopedics and traumatology departments. The main purpose of this article is to discuss how orthopedic oncology clinics should be organized during the pandemic and to present the process management scheme for patients requiring orthopedic surgery, including trauma surgery, from diagnosis to treatment, together with our experiences. Instead of thinking about the global emergence of the epidemic, it is time to act decisively. At first glance, the coronavirus disease 2019 (COVID‐19) pandemic and orthopedics may seem to be unrelated disciplines, but the provision of healthcare services to patients who require them proves that these two fields are parts of the same whole. Our experiences in treating neutropenic, lymphocytopenic, and chemotherapy patients seem to have proven beneficial during this process. We operated on 10 biopsy patients, 15 primary bone sarcomas, 9 soft tissue sarcomas, and 82 trauma patients within this time frame. Only three patients were suspected to have COVID‐19 before admission. The early identification, strict isolation, and effective treatment of these patients prevented any nosocomial infections and disease‐related comorbidities. This success is the result of the multidisciplinary cooperation of the Ministry of Health, our hospital, and our clinic.
Background: This study aimed to investigate the effect of intravenous tranexamic acid (TXA) on blood loss and transfusion rates in children who underwent resection and endoprosthetic reconstruction of distal femoral osteosarcomas. Methods: The medical records of 56 patients who underwent resection and endoprosthetic reconstruction for distal femoral osteosarcomas between 2017 and 2019 were retrospectively reviewed. Patients were divided into 2 groups: group 1 consisted of 25 patients (11 male and 14 female, mean age 15.2 ± 3 y) who received preoperative 15 mg/kg intravenous TXA, and group 2 consisted of 31 control patients (18 male and 13 female, mean age 14.3 ± 2.6 y) who did not receive TXA. The groups were compared based on their total blood loss, intraoperative blood loss, hidden blood loss, postoperative drain output, transfusion requirements, preoperative and postoperative hemoglobin (Hb) and hematocrit (Htc) difference, length of hospital stays, operative time, and complications. Results: The mean total blood loss was lower in intravenous TXA group (1247.5 ± 300.9 mL) when compared with control group (1715.7 ± 857.0 mL) (P = 0.018). The mean intraoperative blood loss in intravenous TXA group (386 ± 109 mL) was lower than that in control group (977.4 ± 610.7 mL) (P < 0.001). Postoperative drain output at 24 and 48 hours was 198.0 ± 61.8 and 72.4 ± 27.4 mL in intravenous TXA group, respectively, and was low compared with 268.4 ± 118.2 and 117.1 ± 67.8 mL in control group (P = 0.028 and 0.006). The rate of patients requiring transfusion was significantly lower in intravenous TXA group (56%) than in control group (83.9%). Preoperative and postoperative 6, 24, and 72 hours Hb and Htc differences were significantly lower in intravenous TXA group [(−1.7 ± 1.8 g/dL P < 0.001; −2.0 ± 1.5 g/dL P < 0.001; −2.3 ± 1.7 g/dL P < 0.001, for Hb) (−5.7 ± 4.6, P < 0.001; −6.9 ± 4.0, P < 0.001; −9.6 ± 9.1, P < 0.001, for Htc)]. Intravenous TXA group had shorter hospital stay time in comparison to control group (P < 0.001). The operative time was significantly longer in the control group (P < 0.05). No increase in pulmonary embolism or venous thromboembolism rate was observed with intravenous TXA use. Conclusion:We conclude that administration of intravenous TXA reduces intraoperative and postoperative blood loss, transfusion rates, and hospital stay in resection and endoprosthetic reconstruction of the distal femoral osteosarcomas in children. Type of Study: This was a retrospective comparative study. Level of Evidence: Level III.
Objective: Successful treatment of intertrochanteric fractures depends on an appropriate implant and is decided according to fracture classification and stability. In the present study, the purpose was to investigate the interobserver and intraobserver consistency of x-ray and/or Computed Tomography (CT) in fracture classification and implant preference for treatment in intertrochanteric fractures. Materials and Methods: The patients who were diagnosed with 80 intertrochanteric fractures by two orthopedists with 5 or more years of trauma experience and who had pelvic CT scans for suspected accompanying fractures were evaluated in the study. AO/OTA classification and implant preference for treatment were based on x-ray and/or CT. Second evaluations were made two weeks later. Cohen’s Kappa was calculated for interobserver reliability in the first evaluation and intraobserver reliability in the first and second evaluations. Results: Intra-observer ICC ranged between 0.861 and 0.973 for Observer-1 and between 0.893 and 0.993 for Observer-2 in all evaluations. Inter-observer ICC was within the range of 0.865-0.961 based on primary evaluations. These data represented excellent intra- and inter-observer consistency for both observers (P
Aim: In the present study, the purpose was to investigate the effects of environmental and personal risk factors on accidents in the motor courier business, which expanded with the pandemic. Material and Method: A total of 227 patients who applied to the Emergency Department after motorcycle accidents between After Pandemic (AP) March 2020-March 2022 and Before Pandemic (BP) March 2018-March 2020 period were included in the study. Statistical differences were analyzed regarding the number of motorcycle accidents before and after the pandemic, the occupation of the patients, driving experiences, weather conditions, and the timing of the accident. Results: No statistically significant differences were detected between the mean age, gender distribution, occupational distribution, accident occurrence time, and duration of experience of the patients in motorcycle accidents admitted to the Emergency Department (p>0.05). Statistically significant differences were detected between the weekly working hours of the patients BP and AP (p
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.